34. Thermo Fisher Scientific (TMO)
Number of Hedge Funds: 113 (2025Q4)
Number of Hedge Funds: 121 (2025Q3)
The shift in Thermo Fisher Scientific (TMO) positions as of February 2026 reflects a classic “high-quality consolidation.” While the number of bullish hedge fund positions trimmed from 122 to 113, the analysis of the data suggests that the remaining institutional “anchor” investors are actually strengthening their conviction in the company’s long-term growth.
1. Institutional Consolidation: The “Quality Over Quantity” Shift
Although some generalist funds exited, the largest and most sophisticated institutional players are holding firm or increasing their concentration.
- The Vanguard Effect: Vanguard Group remains the largest holder with over 34 million shares, a position valued at a staggering $19.78 billion.
- Global Powerhouse Backing: BlackRock and State Street hold massive stakes valued at $17.7 billion and $9.6 billion, respectively.
- High-Conviction Portfolios: Despite the slight drop in fund count, TMO remains one of the “10 Best Life Sciences Stocks to Buy According to Hedge Funds” in early 2026. This indicates that while “tourist” investors may be leaving, the industry specialists are staying put.
2. Fundamental Resilience and Bullish Outlook
The decline in fund count is widely attributed to tactical profit-taking following a strong recovery in late 2025. However, the fundamental case for 2026 remains exceptionally strong:
- Organic Growth Targets: Analysts, including Daniel Arias of Stifel, recently maintained a Buy rating with a $700 price target, highlighting a “mid-single digit organic growth forecast” for 2026.
- Post-Earnings Re-Rating: Following the January earnings call, institutional sentiment shifted toward the “best strong buy healthcare stocks” category, as TMO showed favorable trends in the life sciences and bioprocessing segments.
- Baron Funds Support: Recent investor letters (such as from Baron Health Care Fund) emphasize that TMO is perfectly positioned to benefit from the “ever-evolving life sciences segment,” which recovered strongly at the start of 2026.
3. Insider Trading: Significant Tactical Selling
As is common with high-performing stocks testing new valuations, insiders have been very active in late 2025 and early 2026. This activity is likely a primary reason for the “cautious” signal some funds are seeing:
- Michel Lagarde (COO): Engaged in a series of large sales in December 2025, offloading approximately 84,000 shares at prices between $563 and $584, totaling over $47 million.
- Executive Suite Activity: Other top leaders, including the CFO Stephen Williamson and CHRO Lisa Britt, have also executed recent transactions in February 2026.
- Context: These sales are occurring at price points that reflect significant appreciation, often viewed by institutions as “rebalancing” rather than a lack of fundamental faith in the business.
Summary Verdict
The drop from 122 to 113 funds isn’t a “red flag”—it’s a refining of the shareholder base. The world’s largest asset managers are maintaining multi-billion dollar stakes, and with a $700 price target from key analysts, the consensus is that Thermo Fisher remains the “gold standard” in healthcare infrastructure for 2026.
